Celcuity Q2 net loss widens to $23.7M; VIKTORIA-1 PIK3CA WT cohort enrollment delayed to Q4 2024

Celcuity Inc.

2024-Q2 EPS reported -$1.26

Net loss of $23.7M ($0.62/share) vs $14.6M ($0.66/share) YoY; non-GAAP adjusted loss per share $0.58.
R&D expenses rose to $22.5M, driven by VIKTORIA-1 Phase 3 and initiation of Phase 1b/2 mCRPC trial.
Raised $129M gross from equity and debt financings, extending cash runway through 2026.
VIKTORIA-1 PIK3CA WT cohort enrollment target shifted to Q4 2024; topline data expected late Q4 2024 to Q1 2025.
Plan to initiate Phase 3 VIKTORIA-2 trial in first-line HR+/HER2- advanced breast cancer; first patient expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.